EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives

Anna Balata iD, Katarzyna Pogoda iD

Antibodies · 25.12.2025 · 15 (1) · 3

DOI: 10.3390/antib15010003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 25.12.2025. Verfasst von Anna Balata und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains the most common malignancy and one of the leading causes of cancer-related death among women worldwide. Advances in antibody-based therapies have improved outcomes across all biological subtypes: HER2-positive, triple-negative, and luminal breast cancer. Monoclonal antibodies such as trastuzumab and pertuzumab have established HER2-targeted therapy as a standard of care, while immune checkpoint inhibitors have introduced immunotherapy into the treatment of triple-negative breast cancer. The emergence of antibody–drug conjugates (ADCs), including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan, has further expanded the available therapeutic options. Bispecific antibodies represent a new generation of agents with the potential to overcome resistance and enhance immune activation. Despite impressive progress, important challenges remain, including resistance mechanisms and the management of treatment-related toxicities. This review summarizes the biological rationale, clinical evidence, resistance mechanisms, and safety profiles of therapies based on monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates in breast cancer. The development of these treatment modalities fosters the implementation of personalized, immunologically informed treatment strategies that are redefining precision oncology in breast cancer.

Schlagwörter

Stichwörter der Autor:innen

HER2-positive breast cancerantibody–drug conjugatesbispecific antibodiesbreast cancerhormone receptor–positive HER2-negative breast cancermonoclonal antibodiestriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02781 Warsaw, Poland.

ORCID-Profile: Anna Balata, Katarzyna Pogoda

Zitieren

APA

Balata, A., & Pogoda, K. (2025). Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. Antibodies, 15(1), 3. https://doi.org/10.3390/antib15010003

Vancouver

Balata A, Pogoda K. Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. Antibodies. 2025;15(1):3. doi:10.3390/antib15010003

BibTeX
@article{Balata2025,
  author = {Balata, Anna and Pogoda, Katarzyna},
  title = {Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives},
  journal = {Antibodies},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {3},
  doi = {10.3390/antib15010003}
}
Kostenlos starten →